IGI Logo

Shilpa Medicare is currently trading at Rs. 653.10, up by 9.35 points or 1.45% from its previous closing of Rs. 643.75 on the BSE.

The scrip opened at Rs. 656.60 and has touched a high and low of Rs. 674.55 and Rs. 627.85 respectively. So far 20799 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 685.00 on 12-Jul-2024 and a 52 week low of Rs. 296.45 on 26-Oct-2023.

Last one week high and low of the scrip stood at Rs. 674.55 and Rs. 615.25 respectively. The current market cap of the company is Rs. 6309.96 crore.

The promoters holding in the company stood at 44.39%, while Institutions and Non-Institutions held 16.69% and 38.92% respectively.

Shilpa Medicare’s wholly owned subsidiary -- Shilpa Biologicals (SBPL) has received registration approval for Adalimumab from Morocco, MoH. This is the first Biosimilar approval from any international market for high concentration Adalimumab developed by SBPL. 

Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL). Adalimumab contains Adalimumab as an active ingredient. Adalimumab is a fully human monoclonal IgG1 antibody produced recombinantly by Chinese Hamster Ovary (CHO) cells. Adalimumab consists of 1330 amino acid containing glycoprotein which has two copies of heavy- and two copies of light-chains in heterodimeric form with a molecular weight of 148 kDa (approximate). 

SBPL has aggressively submitted its Adalimumab dossier in more than 15 emerging markets countries and is in the process of submitting the dossier to other countries as well.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.